These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Prevalence of anti-PF4/heparin antibodies and the HIT syndrome in cardiovascular medicine. Mattioli AV Semin Thromb Hemost; 2004 Jun; 30(3):291-5. PubMed ID: 15282651 [TBL] [Abstract][Full Text] [Related]
52. Heparin-induced thrombocytopenia. Bambrah RK; Pham DC; Zaiden R; Vu H; Tai S Clin Adv Hematol Oncol; 2011 Aug; 9(8):594-9. PubMed ID: 22236986 [TBL] [Abstract][Full Text] [Related]
53. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Juhl D; Eichler P; Lubenow N; Strobel U; Wessel A; Greinacher A Eur J Haematol; 2006 May; 76(5):420-6. PubMed ID: 16466367 [TBL] [Abstract][Full Text] [Related]
55. HITlights: a career perspective on heparin-induced thrombocytopenia. Warkentin TE Am J Hematol; 2012 May; 87 Suppl 1():S92-9. PubMed ID: 22367928 [TBL] [Abstract][Full Text] [Related]
56. Heparin-Induced thrombocytopenia: minimising the risks in the elderly patient. Tardy-Poncet B; Tardy B Drugs Aging; 2000 May; 16(5):351-64. PubMed ID: 10917073 [TBL] [Abstract][Full Text] [Related]
57. Incidence and clinical outcomes of heparin-induced thrombocytopenia: 11 year experience in a tertiary care university hospital. Cosmi B; Legnani C; Cini M; Borgese L; Sartori M; Palareti G Intern Emerg Med; 2023 Oct; 18(7):1971-1980. PubMed ID: 37568069 [TBL] [Abstract][Full Text] [Related]
58. Immunologic Effects of Heparin Associated With Hemodialysis: Focus on Heparin-Induced Thrombocytopenia. Warkentin TE Semin Nephrol; 2023 Nov; 43(6):151479. PubMed ID: 38195304 [TBL] [Abstract][Full Text] [Related]
59. Heparin-induced thrombocytopenia. Chong BH Aust N Z J Med; 1992 Apr; 22(2):145-52. PubMed ID: 1530537 [TBL] [Abstract][Full Text] [Related]